Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 18, 2012 Sean Williams	This Company is Quickly Approaching the Patent Cliff Earnings exceed expectations at drug manufacturer Forest Laboratories, but worries about future sales mount.
The Motley Fool April 24, 2007 Ryan Fuhrmann	Mixed Foliage at Forest Labs Here's what to look for as Forest Labs prepares for a big loss. Investors, take note.
The Motley Fool October 18, 2005 Stephen D. Simpson	Forest Labs' Clear-Cut Woes Patent litigation, generic competition, and drug development troubles nibble away at this pharmaceutical. Investors, take note.
The Motley Fool January 16, 2008 Brian Orelli	Forest Labs Not Down -- Yet Double-digit revenue growth is the highlight of a good quarter for Forest Labs, but the company will need a lot more than one solid quarter to get its stock growing again.
The Motley Fool January 10, 2007 Rich Duprey	Foolish Forecast: Greener Forest Labs The pharmaceutical firm stands tall against competition. When the company releases its third-quarter 2007 financials, investors shouldn't have to reach for their medicine chest.
The Motley Fool October 18, 2006 Brian Lawler	Seeing the Forest Through the Trees Underappreciated Forest Labs continues its trend of strong growth. Trading at roughly 20 times its forward earnings guidance even with a much higher level of R&D spending, here is a company that investors shouldn't lose sight of amidst the rest of the trees.
The Motley Fool May 1, 2006 Stephen D. Simpson	Short-Term Fears Chip Into Forest Investors may be getting a second chance at unconventional Forest Labs. With the stock having pulled back, it's now very close to a tantalizing price.
The Motley Fool July 18, 2006 Stephen D. Simpson	Survival of the Forest New products and a favorable patent ruling give Forest Labs a boost. Investors, this stock remains one to watch.
The Motley Fool July 14, 2006 Stephen D. Simpson	The Diverging Fortunes of Forest and Teva If a patent ruling holds up, Forest's prospects are much stronger. Unfortunately, the easy money has long since been made in Forest and today's announcement will almost certainly mean another big jump in the stock price.
The Motley Fool September 26, 2011 Christopher Barker	A Monster Rally for Silvercorp Metals While the silver sector swoons, Silvercorp Metals shines.
The Motley Fool October 22, 2009 Robert Steyer	Nibbles Here and There at Forest Labs Forest Laboratories banks on its usual strategy of licensing and collaboration to offset generic-drug threats.
The Motley Fool April 16, 2008 Brian Orelli	Forest Labs' Race Against the Clock Investors don't seem to like Forest Labs' ambitious plans for research and development.
The Motley Fool January 17, 2006 Stephen D. Simpson	Forest Labs: Is Different Better? Forest isn't your typical pharmaceutical company, and that's both its boon and its bane for investors.
The Motley Fool February 22, 2011 Ryan McBride	Forest Labs Snaps Up Clinical Data This deal is the latest proof that drug developers with FDA-approved treatments remain hot buyout targets in a pharma industry that is starved for new products to replace brand-name drugs.
The Motley Fool April 19, 2005 Stephen D. Simpson	Does Forest Have the Blues? Hugely dependent on a single drug, Forest is in a precarious position. Though the next couple of years could be a little hairier than what most pharma investors are normally accustomed to, Forest is worth a look.
The Motley Fool September 7, 2011 Christopher Barker	Setting the Record Straight on Silvercorp Metals Silvercorp Metals offers a comprehensive rebuttal of anonymous allegations.
BusinessWeek June 12, 2006 Gene G. Marcial	New Growth At Forest? Forest Laboratories has been a drag among drugmakers.
The Motley Fool October 18, 2006 Rich Duprey	FDA Expands Alzheimer's Treatment Japan's fourth-largest pharmaceutical Eisai's Aricept wins the right to treat all stages of Alzheimer's. Investors, take note.
The Motley Fool October 16, 2007 Billy Fisher	Forest Labs Isn't Out of the Woods Yet The drugmaker's Q2 profit falls, but the company raises its full-year forecast.
The Motley Fool October 30, 2007 Billy Fisher	Is Forest Labs' Nebivolol Ready for Prime Time? Shareholders of the pharmaceutical company have been looking for a way to boost their floundering stock. The FDA's likely approval of hypertension drug Nebivolol may be the answer.
The Motley Fool October 5, 2004 W.D. Crotty	Lots of Profits in This Forest Drug manufacturer Forest Laboratories, down sharply from its high, offers value and growth.
The Motley Fool August 30, 2010 Anders Bylund	Silver Wheaton Is a Bottle Rocket Buy high and sell higher!
The Motley Fool August 1, 2011 Sean Williams	Shorts Are Piling Into These Stocks -- Should You Be Worried? Are short-sellers trying to tell you something about these stocks?
The Motley Fool December 12, 2005 Rich Duprey	Patent? What Patent? Japanese drug firm Eisai sues Teva over a patented Alzheimer's treatment. Investors, take note.
The Motley Fool March 31, 2005 Stephen D. Simpson	Another "No" for Lexapro This latest FDA setback shouldn't hurt Forest Labs much, and the shares look like a bargain.
The Motley Fool April 14, 2008 Brian Orelli	Teva Gets What It Wants Teva persuades a court to order the FDA to award it a marketing exclusivity for generic Risperdal.
The Motley Fool June 1, 2005 Rich Duprey	Able Labs Disabled The generic drug maker recalls its entire inventory over quality concerns. Its stock price cratered 75% the day after the announcement and has since fallen another 30% since then.
The Motley Fool July 19, 2005 Stephen D. Simpson	A Clearing in the Forest? Despite so-so results, the biotech stock's slide may finally be over.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
The Motley Fool September 11, 2007 Brian Orelli	Teva Spending Plenty of Time in Court Three patent disputes in one week keeps the lawyers busy: Teva and Novartis have been locked in dispute over Novartis' Famvir tablets... Teva and Forest spar over patents for Lexapro... Teva and Wyeth argue over Protonix...
The Motley Fool September 1, 2004 W.D. Crotty	A Pall Falls Over Forest One of Forest Labs' Alzheimer's drugs fails in phase 3 trials. For investors willing to take the political risk, today's drug news has taken a battered stock, with a great balance sheet, to very reasonable price levels.
The Motley Fool December 19, 2005 Stephen D. Simpson	Pfizer Wins, a Sector Rejoices The pharmaceutical dodges a bullet and investors find renewed enthusiasm for big-cap pharma.
The Motley Fool May 20, 2010 Dave Mock	A Big Upgrade for Silvercorp Metals This bullish call comes from more than just one analyst.
The Motley Fool November 29, 2005 Stephen D. Simpson	Forest Seeds Future Growth A new deal with long-term benefits signals that the pharmaceutical remains credible. Patient investors may yet find this stock worth some due diligence.
The Motley Fool April 25, 2011 Sean Williams	Pharma's Most Impervious Pipeline An investment in generics doesn't have to be a bad thing.
The Motley Fool August 30, 2010 Dave Mock	A Big Upgrade for Hecla Mining After spending much of the past year at a middle-of-the-road three-star ranking, Hecla Mining has impressed enough top-performing members of the 165,000-strong Motley Fool CAPS community to climb up to four stars.
The Motley Fool August 6, 2011 Sean Williams	10 Large Caps to Rule Them All There's nothing generic about this company. For the inaugural large-cap pick, I think we should revisit pharma's most impervious pipeline, Teva Pharmaceuticals.
The Motley Fool February 22, 2011 Brian Orelli	Timber! Clinical Data Falls. Forest Labs cuts down Clinical Data. Clinical Data announced today that it agreed to be purchased by Forest Labs for $30 per share.
The Motley Fool November 8, 2005 Stephen D. Simpson	Teva Is No Generic Generics Firm Although 2005 wasn't a great year for generics on the whole, 2006 is shaping up to be pretty interesting for Teva. Is it time to buy these shares?
The Motley Fool December 30, 2008 Brian Orelli	2009's Generic Drugs: Who's at Risk The patent cliff is coming early for some drugmakers.
The Motley Fool February 28, 2008 Brian Lawler	Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year.
The Motley Fool May 10, 2006 Stephen D. Simpson	Time to Make Room for Teva? This might be a rare chance to pick up a dominant company at an attractive price. Investors, take note.
The Motley Fool September 23, 2008 Brian Lawler	Will Generic Biologics Get Special Treatment? While the rest of the market was lost in the financial meltdown, a little-noticed report discussing some of the biopharmaceutical bills going through Congress was released.
The Motley Fool June 6, 2005 Stephen D. Simpson	"Bad News" for Teva? Yawn... Be ready to act when the market overreacts. For those investors who think that Teva Pharmaceutical will maintain its top-dog status in the generics world, this is just a blip on the scope and/or the opportunity to build a position.
The Motley Fool December 12, 2007 Brian Lawler	Patent Bill Is No Panacea A new bill that was meant to strengthen the patent and other intellectual-property rights of drugmakers doesn't do enough to encourage pharma innovation.
The Motley Fool September 30, 2005 Stephen D. Simpson	Two Pharma Trees Fall The news of a phase 3 trial failure hammers both Forest Labs and Cypress Bioscience. Investors, take note.
The Motley Fool February 28, 2011 Christopher Barker	Skeletons Emerge From Hecla's Closet Hecla Mining delayed its fourth-quarter earnings release in order to report on the progress of ongoing efforts to settle litigation brought by the Coeur d'Alene Indian Tribe and the federal government during the 1990s.
The Motley Fool April 12, 2004 Brian Gorman	Forest Labs Faces Skeptics Its star drug Namenda, a new treatment for Alzheimer's disease, is taking heat from doctors.
The Motley Fool January 21, 2004 Alyce Lomax	Forest Labs' High Hopes Alzheimer's treatment drug Namenda seems to be Forest's strong suit.